Palvella Therapeutics Book Value Per Share Growth & History (PVLA)
Palvella Therapeutics's book value per share was $2.26 for fiscal 2025.
View full Palvella Therapeutics company overviewPalvella Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.26 | -$3.43 | −60.25% |
| 2024 | 2024-12-31 | $5.69 | $47.76 | — |
| 2023 | 2023-12-31 | -$42.08 | $58.60 | — |
| 2022 | 2022-12-31 | -$100.67 | -$156.89 | — |
| 2021 | 2021-12-31 | $56.22 | $11.90 | +26.85% |
| 2020 | 2020-12-31 | $44.32 | -$30.08 | −40.43% |
| 2019 | 2019-12-31 | $74.41 | $15.41 | +26.12% |
| 2018 | 2018-12-31 | $59.00 | $38.52 | +188.13% |
| 2017 | 2017-12-31 | $20.48 | -$26.39 | −56.31% |
| 2016 | 2016-12-31 | $46.87 | -$15.65 | −25.03% |
| 2015 | 2015-12-31 | $62.52 | $13.32 | +27.07% |
| 2014 · Dec 31 | 2014-12-31 | $49.20 | $45.24 | +1143.51% |
| 2014 · Jun 30 | 2014-06-30 | $0.13 | — | — |
| 2013 | 2013-12-31 | $3.96 | — | — |
Palvella Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $15.06 | $10.74 | +248.70% |
| Q1 2026 | 2026-03-31 | $16.23 | $11.19 | +221.86% |
| Q4 2025 | 2025-12-31 | $2.26 | -$3.43 | −60.25% |
| Q3 2025 | 2025-09-30 | $3.49 | $69.69 | — |
| Q2 2025 | 2025-06-30 | $4.32 | $65.54 | — |
| Q1 2025 | 2025-03-31 | $5.04 | $67.20 | — |
| Q4 2024 | 2024-12-31 | $5.69 | $47.76 | — |
| Q3 2024 | 2024-09-30 | -$66.20 | -$90.89 | — |
| Q2 2024 | 2024-06-30 | -$61.22 | -$94.00 | — |
| Q1 2024 | 2024-03-31 | -$62.16 | -$78.76 | — |
| Q4 2023 | 2023-12-31 | -$42.08 | $58.60 | — |
| Q3 2023 | 2023-09-30 | $24.69 | -$13.76 | −35.79% |
| Q2 2023 | 2023-06-30 | $32.77 | -$15.02 | −31.43% |
| Q1 2023 | 2023-03-31 | $16.59 | -$41.11 | −71.24% |
| Q4 2022 | 2022-12-31 | -$100.67 | -$156.89 | — |
| Q3 2022 | 2022-09-30 | $38.46 | -$21.80 | −36.17% |
| Q2 2022 | 2022-06-30 | $47.80 | -$8.26 | −14.73% |
| Q1 2022 | 2022-03-31 | $57.71 | $6.49 | +12.66% |
| Q4 2021 | 2021-12-31 | $56.22 | $11.90 | +26.85% |
| Q3 2021 | 2021-09-30 | $60.25 | -$2.20 | −3.52% |
| Q2 2021 | 2021-06-30 | $56.05 | -$15.20 | −21.33% |
| Q1 2021 | 2021-03-31 | $51.22 | -$20.95 | −29.02% |
| Q4 2020 | 2020-12-31 | $44.32 | -$30.08 | −40.43% |
| Q3 2020 | 2020-09-30 | $62.45 | $29.02 | +86.79% |
| Q2 2020 | 2020-06-30 | $71.26 | $39.61 | +125.19% |
| Q1 2020 | 2020-03-31 | $72.17 | $23.07 | +47.00% |
| Q4 2019 | 2019-12-31 | $74.41 | $15.41 | +26.12% |
| Q3 2019 | 2019-09-30 | $33.43 | -$40.82 | −54.97% |
| Q2 2019 | 2019-06-30 | $31.64 | -$50.29 | −61.38% |
| Q1 2019 | 2019-03-31 | $49.09 | -$26.04 | −34.66% |
| Q4 2018 | 2018-12-31 | $59.00 | $38.52 | +188.13% |
| Q3 2018 | 2018-09-30 | $74.25 | $66.10 | +810.32% |
| Q2 2018 | 2018-06-30 | $81.94 | $64.90 | +381.06% |
| Q1 2018 | 2018-03-31 | $75.14 | $41.63 | +124.22% |
| Q4 2017 | 2017-12-31 | $20.48 | -$26.39 | −56.31% |
| Q3 2017 | 2017-09-30 | $8.16 | -$50.34 | −86.05% |
| Q2 2017 | 2017-06-30 | $17.03 | -$52.25 | −75.42% |
| Q1 2017 | 2017-03-31 | $33.51 | -$21.07 | −38.61% |
| Q4 2016 | 2016-12-31 | $46.87 | -$15.65 | −25.03% |
| Q3 2016 | 2016-09-30 | $58.49 | -$9.22 | −13.61% |
| Q2 2016 | 2016-06-30 | $69.28 | $38.98 | +128.65% |
| Q1 2016 | 2016-03-31 | $54.58 | $15.90 | +41.12% |
| Q4 2015 | 2015-12-31 | $62.52 | $13.32 | +27.07% |
| Q3 2015 | 2015-09-30 | $67.71 | $67.72 | — |
| Q2 2015 | 2015-06-30 | $30.30 | $30.17 | +22973.03% |
| Q1 2015 · Mar 31 | 2015-03-31 | $38.68 | $38.71 | — |
| Q4 2014 · Dec 31 | 2014-12-31 | $49.20 | $45.24 | +1143.51% |
| Q1 2015 · Sep 30 | 2014-09-30 | -$0.01 | — | — |
| Q4 2014 · Jun 30 | 2014-06-30 | $0.13 | $0.10 | +294.73% |
| Q1 2014 | 2014-03-31 | -$0.03 | — | — |
| Q4 2013 | 2013-12-31 | $3.96 | — | — |
| Q2 2013 | 2013-06-30 | $0.03 | — | — |
Palvella Therapeutics book value per share trends
Over the last five fiscal years, Palvella Therapeutics's book value per share decreased from $44.32 to $2.26, a change of -$42.06. The latest reported quarter, Q2 2026, shows $15.06.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Palvella Therapeutics source filings ↗